Investment
Backed TYBR Health's $30M Series A financing to expand access to the B3 GEL System.
TYBR Health
JUL 21, 2026
Exit
Portfolio company SpyGlass Pharma priced its initial public offering (NASDAQ: SGP).
SpyGlass Pharma
FEB 6, 2026
Every public signal F4 has attached to this firm, with sources and cross-entity links.
TYBR Health
SpyGlass Pharma
Ventaris Surgical
Apella Technology
Okami Medical
Thomas Tu, MD joins as Venture Partner; Vensana Innovation launches
Luna Diabetes
Maria Berkman joins as Partner; Ross Segan joins as Venture Partner
SpyGlass Pharma
Rampart IC
Evident Vascular
Alleviant Medical
Vensana Capital Fund III
Cleerly